Aurobindo Pharma has informed that it enclosed the Press Release that is being issued by the Company in connection with USFDA approval received by Eugia Pharma Specialities, a wholly owned subsidiary of the Company, for Budesonide Inhalation Suspension, 0.5 mg/2 mL Single-Dose Ampule.
The above information is a part of company’s filings submitted to BSE.